OTSKY Stock UPDATES Otsuka Holdings Co. (OTSKY) 18.1200 08/30/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Otsuka Holdings Co. (OTSKY) 18.1200 $OTSKY

Dementia Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pmw68m/dementia) has announced the addition of the "Dementia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dementia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Sylentis S.A. - FORUM Pharmaceuticals Inc. - Ildong Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - WhanIn Pharmaceutical Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Summit Corporation plc - Oryzon Genomics S.A. - Intellect Neurosciences, Inc. - Intra-Cellular Therapies, Inc. - Tautatis Incorporated - Pacific Northwest Biotechnology, LLC - Otsuka Holdings Co., Ltd. - Chase Pharmaceuticals Corporation - Echo Pharmaceuticals B.V. - Chronos Therapeutics Limited - Alector LLC - ImStar Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/pmw68m/dementia

Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018
M2 - Wed Jul 02, 2:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpvs7l/global_glaucoma) has announced the addition of the "Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018" report to their offering. Glaucoma is a disease of the eye in which fluid pressure within the eye increases. If left untreated the patient may lose vision and even become blind. The exact etiology of optic nerve damage due to glaucoma is not fully known, but involves mechanical compression and/or decreased blood flow in the optic nerve. Based on whether the cause of the disease is unknown or known, glaucoma is divided into two types, open angle and closed angle glaucoma. Five main classes of medical treatment are currently used to lower intraocular pressure: prostaglandins, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, and fixed dose combinations. The Global Glaucoma Therapeutics market can be divided into five segments: Prostaglandins, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, and Fixed Dose Combinations. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Glaucoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Allergan Inc. - Merck & Co. Inc. - Novartis AG - Pfizer Inc. Other Prominent Vendors - Acadia Pharmaceuticals Inc. - AC Immune SA - Acorn Biomedical Inc. - Advanced Cell Technology Inc. - Aerie Pharmaceuticals Inc. - Carl Zeiss Meditec Inc. - Falcon Pharmaceuticals Ltd. - Inotek Pharmaceuticals Corp. - Lexicon Pharmaceuticals Inc. - Neurotech Pharmaceuticals Inc. - NicOx SA - Otsuka Holdings Co. Ltd. - Phytopharm plc - Santen Pharmaceuticals Co. Ltd. - Senju Pharmaceutical Co. Ltd. - SIFI SpA - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zp...l_glaucoma

Autism - Pipeline Review, H1 2014 - 20 Companies & 42 Drug Profiles
M2 - Fri Jun 20, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzhjv/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - Merz Pharma GmbH & Co. KgaA - Teva Pharmaceutical Industries Limited - Avanir Pharmaceuticals, Inc. - Snowdon Inc. - Curemark, LLC - Coronado Biosciences, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Cellceutix Corporation - Heptares Therapeutics Ltd. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Naurex, Inc. - Nectid, Inc. - Mnemosyne Pharmaceuticals, Inc. - BioCrea GmbH - Saniona AB Drug Profiles - CM-AT - lurasidone hydrochloride - aripiprazole - cycloserine - fluoxetine - oxytocin - oxytocin - memantine hydrochloride - TSO - pioglitazone hydrochloride - oxytocin - oxytocin - (dextromethorphan hydrobromide quinidine sulfate) - oxytocin - oxytocin - RG-7314 - fluoxetine - fluoxetine - argipressin tannate - NU-211-01 NC-215-01 - Autologous Hematopoietic Stem Cells - glatiramer acetate - ITI-007 - Stem Cell Therapy for Central Nervous System Disorders - KM-391 - Program For Neurological Disorders - STX-110 - CN-2097 - acamprosate calcium - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome For more information visit http://www.researchandmarkets.com/research/lt...m_pipeline

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014: 16 Companies & 27 Drugs Profiled
M2 - Thu Jun 19, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhf5zs/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Nanotherapeutics, Inc. - Neurocrine Biosciences, Inc. - Addex Therapeutics - Neuralstem, Inc. - Catalyst Pharmaceutical Partners, Inc. - Humanetics Corporation - NeuroNascent, Inc. - Azevan Pharmaceuticals, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Vanda Pharmaceuticals Inc. - Marinus Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Tonix Pharmaceuticals Holding Corp. - Sage Therapeutics - Istituto Italiano di Tecnologia Drug Profiles - brexpiprazole - PRX-3140 - verucerfont - atorvastatin calcium - aprepitant - ganaxolone - iloperidone - mifepristone - oxytocin - 7-Keto - SRX-251 - SRX-246 - ITI-007 - NNI-351 - mGluR7-NAM Program For Central Nervous System Disorders - NSI-189 - cyclobenzaprine hydrochloride - S-107 - Small Molecule Targeting GABAA Receptor For Post Traumatic Stress Disorder - ZL-006 - ADX-71743 - Dihydroxyflavone - TLR-4 Antagonists for CNS Disorders - Immune Therapy For PTSD and Depression - Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders - Small Molecules to Inhibit FAAH for CNS Disorders - vigabatrin For more information visit http://www.researchandmarkets.com/research/hh...ttraumatic

Global Autism Clinical Trials Review 2014
M2 - Tue Jun 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhfbw6/autism_global) has announced the addition of the "Autism Global Clinical Trials Review, H1, 2014" report to their offering. Autism Global Clinical Trials Review, H1, 2014 provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Autism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Autism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Autism Speaks, Inc. - Seaside Therapeutics, LLC - Forest Laboratories, Inc. - Johnson & Johnson - Otsuka Holdings Co., Ltd. - F. Hoffmann-La Roche Ltd. - Bristol-Myers Squibb Company - Coronado Biosciences, Inc. - ZonMw - Dainippon Sumitomo Pharma Co., Ltd. - National Institute of Mental Health - Massachusetts General Hospital - Tehran University of Medical Sciences - Eunice Kennedy Shriver National Institute of Child Health and Human Development - Hugo W. Moser Research Institute at Kennedy Krieger, Inc. - Stanford University - The University of Hong Kong - University of California, Los Angeles - Mount Sinai Hospital - University of California, San Francisco For more information visit http://www.researchandmarkets.com/research/vh...ism_global

Ocular Hypertension - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bzfhkc/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Kowa Company, Ltd. - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Can-Fite BioPharma Ltd. - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - D. Western Therapeutics Institute, Inc. - Icon Bioscience, Inc. - Otsuka Holdings Co., Ltd. - Ocular Therapeutix, Inc. - Amakem NV - High Point Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/bzfhkc/ocular

Liver Cirrhosis Global Clinical Trials Review, H2 2013 is Essential Reading for those in Medical Field
M2 - Tue Jan 14, 9:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/rtmwq9/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Liver Cirrhosis Global Clinical Trials Review, H2, 2013" provides data on the Liver Cirrhosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Cirrhosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Cirrhosis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - Assistance Publique - Hopitaux de Paris - Astellas Pharma Inc. - Beijing Friendship Hospital - F. Hoffmann-La Roche Ltd. - Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - Genextra S.p.a. - Medical University of Vienna - Merck & Co., Inc. - Novartis AG - Okayama University - Otsuka Holdings Co., Ltd. - Pharmicell Co., Ltd. - Royal Prince Alfred Hospital - Sanofi - Stempeutics Research Private Limited For more information visit http://www.researchandmarkets.com/research/rt..._cirrhosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Finkelstein Thompson LLP Announces Investigation of Astex Pharmaceuticals, Inc. Buyout
Business Wire - Thu Sep 05, 10:24AM CDT
The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) ("Astex" or "the Company" , concerning the Company's proposed acquisition by Otsuka Holdings Co., Ltd. (TYO: 45780) ("Otsuka" . Under the terms of the merger agreement, Astex shareholders will receive $8.50 in cash for each share of Astex common stock they own. The total transaction is valued at approximately $886 million. At least one analyst has set a target price of $13.00 for Astex shares.

Research and Markets: Supplement Market in the US 2012-2016 with NBTY Inc., Otsuka Holdings Co. Ltd., and Perrigo Co. Dominating
Business Wire - Thu Aug 15, 1:32PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlh45q/supplement_market) has announced the addition of the "Supplement Market in the US 2012-2016" report to their offering.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 57

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 65

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 108

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
CATL Makes Its APEC Case Beyond the Electric Car Market

Updated Category News Views 135

A 99-Second Pitch With Bigger Ambitions Battery swapping got a rare moment in the geopolitical sunlight at Shenzhen's APEC CEO Summit, and CATL was plainly trying to make that moment count. Dr. Robin Zeng, the company's founder, chairman and chief executive, used the opening business dialogue to argue that the Asia-Pacific region holds more opportunity than trouble. Fair...

Continue Reading
Frontline Claims Survey Tests AI's Real Desk Impact

Updated Category News Views 113

Claims software can look brilliant in a conference-room demo and still create a fresh pile of headaches for the person handling a real injured worker’s file. That is why the 2026 Workers’ Compensation Benchmarking Study opening its survey to frontline claims professionals matters more than the usual industry questionnaire. This is an operating-reality check, not just...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 190

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 199

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
iFLYTEK’s AINOTE Discounts Put E-Ink Utility on Trial

Updated Category News Views 75

A slim E-Ink notebook is getting shoved into the Black Friday brawl, and iFLYTEK is betting that less screen glare and more follow-through can still command a serious price. The company has put discounts of up to 25% on its AINOTE lineup, a sensible move in a gadget season where buyers have no shortage of tablets, voice apps, and half-used productivity subscriptions...

Continue Reading
Luxor Targets Device Chaos With Kwik IQ Hub Lockers

Updated Category News Views 86

A dead scanner at shift change can make an expensive digital rollout look downright foolish. Luxor Workspaces is aiming squarely at that unglamorous mess with its newly available Kwik IQ Hub smart-locker collection, introduced at the Connected Worker: Manufacturing Summit in Chicago on October 13–15. The pitch is not flashy: put shared radios, scanners, headsets,...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 198

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading

Top 5 Most Recently Viewed Articles

Insightful Update on Scully Royalty's Annual Meeting Plans

Updated Category News Views 129

Insightful Overview of Scully Royalty's Annual Meeting Scully Royalty Ltd. (NYSE: SRL) has recently provided valuable insights regarding its upcoming annual general meeting (AGM) scheduled for December 27, 2025. This update follows a noteworthy event involving MILFAM LLC, which filed a purported dissident proxy circular aimed at nominating five candidates for the...

Continue Reading
How a $1,000 Bitcoin Investment Shaped Financial Perspectives

Updated Category News Views 353

The Shift in Bitcoin's Investment Landscape Cryptocurrency has turned into a financial wild west, where fortunes are made and lost at lightning speed. At the center of this universe is Bitcoin, once brushed off by many traditional financiers. One such critic was Jamie Dimon, CEO of JPMorgan & Chase, who didn't hold back his disdain for the digital currency. Dimon’s...

Continue Reading
Netcompany's Share Buyback Program Progress Report

Updated Category News Views 162

Overview of Netcompany's Share Buyback Program In a strategic move to optimize its capital structure, Netcompany Group A/S has initiated a significant share buyback program aiming to repurchase up to DKK 250 million worth of shares. This action is accompanied by a target to acquire a maximum of 1,300,000 shares, reflecting Netcompany's commitment to fulfilling its...

Continue Reading
Ramaco Resources Partners with Goldman Sachs for Minerals Initiative

Updated Category News Views 133

Collaboration with Goldman Sachs Ramaco Resources, Inc. (NASDAQ: METC, METCB) has taken a significant step forward by teaming up with Goldman Sachs & Co. LLC. This partnership aims to establish a new initiative focused on creating a Strategic Critical Minerals Terminal (SCMT) at Ramaco's Brook Mine facility. Strategic Importance of the SCMT The SCMT initiative, approved...

Continue Reading
Understanding V2X's Upgrade to Buy: Key Insights Revealed

Updated Category News Views 96

Understanding V2X's Current Market Position V2X VVX has recently caught the eye of investors after being upgraded to a "Buy" rating. This upgrade marks a significant shift in earnings estimates, which are pivotal in determining stock valuations. The improved earnings outlook reflects a growing sense of optimism among analysts, boosting the overall attractiveness of the...

Continue Reading